Pfenex Stock Price, News & Analysis (NYSEAMERICAN:PFNX)

$3.45 0.00 (0.00 %)
(As of 02/19/2018 06:00 AM ET)
Previous Close$3.45
Today's Range$3.31 - $3.45
52-Week Range$2.07 - $7.91
Volume12,236 shs
Average Volume122,501 shs
Market Capitalization$81.24 million
P/E Ratio-1.94
Dividend YieldN/A


Pfenex logoPfenex Inc. is a clinical-stage biotechnology company. The Company is engaged in the development of biosimilar and therapeutic equivalent products to branded therapeutics and other high-value and difficult-to-manufacture proteins. Its lead product candidate is PF582, a biosimilar candidate to Lucentis (ranibizumab). Its next advanced product candidates are PF530 and PF708. PF530 is a biosimilar candidate to Betaseron (interferon beta-1b). PF708 is being developed as a therapeutically equivalent peptide to Forteo (teriparatide), which is for the treatment of osteoporosis. In addition to its three advanced product candidates, its pipeline includes over four other biosimilar candidates, as well as vaccines and next generation biologic candidates. Its product candidates are enabled by its protein production platform, Pfenex Expression Technology. It is also developing Px563L, an anthrax vaccine candidate, and Px533 as a prophylactic vaccine candidate against malaria infection.

Receive PFNX News and Ratings via Email

Sign-up to receive the latest news and ratings for PFNX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
SectorBio Therapeutic Drugs


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E Ratio-1.93820224719101
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A


Trailing EPS($1.78)
Net IncomeN/A
Net Margins-175.52%
Return on Equity-63.57%
Return on Assets-46.31%


Outstanding Shares23,550,000

Pfenex (NYSEAMERICAN:PFNX) Frequently Asked Questions

What is Pfenex's stock symbol?

Pfenex trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PFNX."

How were Pfenex's earnings last quarter?

Pfenex Inc (NYSEAMERICAN:PFNX) posted its quarterly earnings data on Thursday, November, 9th. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.54) by $0.17. The biotechnology company earned $5.02 million during the quarter, compared to the consensus estimate of $3.30 million. Pfenex had a negative return on equity of 63.57% and a negative net margin of 175.52%. The firm's quarterly revenue was down 89.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.46 earnings per share. View Pfenex's Earnings History.

When will Pfenex make its next earnings announcement?

Pfenex is scheduled to release their next quarterly earnings announcement on Tuesday, March, 13th 2018. View Earnings Estimates for Pfenex.

Where is Pfenex's stock going? Where will Pfenex's stock price be in 2018?

1 brokers have issued 1-year target prices for Pfenex's stock. Their forecasts range from $8.00 to $8.00. On average, they expect Pfenex's share price to reach $8.00 in the next twelve months. View Analyst Ratings for Pfenex.

Are investors shorting Pfenex?

Pfenex saw a decrease in short interest in the month of January. As of January 31st, there was short interest totalling 184,290 shares, a decrease of 30.3% from the January 12th total of 264,275 shares. Based on an average daily volume of 125,771 shares, the short-interest ratio is presently 1.5 days. Currently, 0.9% of the shares of the company are sold short.

Who are some of Pfenex's key competitors?

Who are Pfenex's key executives?

Pfenex's management team includes the folowing people:

  • Evert B. Schimmelpennink, President, Chief Executive Officer, Acting Principal Financial Officer, Secretary, Director (Age 45)
  • Susan A. Knudson, Chief Financial Officer, Principal Financial Officer (Age 53)
  • Patricia Lady CPA, Chief Accounting Officer (Age 58)
  • Hubert C. Chen M.D., Chief Medical Officer (Age 48)
  • Patrick K. Lucy, Chief Business Officer (Age 49)
  • Robin D. Campbell Ph.D., Independent Director (Age 62)
  • Dennis M. Fenton Ph.D., Independent Director (Age 65)
  • Phillip M. Schneider, Independent Director (Age 60)
  • John M. Taylor III, Independent Director (Age 52)

Who owns Pfenex stock?

Pfenex's stock is owned by many different of institutional and retail investors. Top institutional investors include SANDERS MORRIS HARRIS LLC (5.00%), Franklin Resources Inc. (11.82%), SANDERS MORRIS HARRIS LLC (6.94%), SANDERS MORRIS HARRIS LLC (6.94%), Sanders Morris Harris LLC (5.75%) and Renaissance Technologies LLC (4.29%). Company insiders that own Pfenex stock include Jason Grenfell-Gardner, Patricia Lady, Patrick K Lucy and Signet Healthcare Partners Acc. View Institutional Ownership Trends for Pfenex.

Who sold Pfenex stock? Who is selling Pfenex stock?

Pfenex's stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Perceptive Advisors LLC and C WorldWide Group Holding A S. View Insider Buying and Selling for Pfenex.

Who bought Pfenex stock? Who is buying Pfenex stock?

Pfenex's stock was purchased by a variety of institutional investors in the last quarter, including Sanders Morris Harris LLC, Mackenzie Financial Corp, Renaissance Technologies LLC, Millennium Management LLC, Spark Investment Management LLC, Franklin Resources Inc. and Deutsche Bank AG. View Insider Buying and Selling for Pfenex.

How do I buy Pfenex stock?

Shares of Pfenex can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pfenex's stock price today?

One share of Pfenex stock can currently be purchased for approximately $3.45.

How big of a company is Pfenex?

Pfenex has a market capitalization of $81.24 million.

How can I contact Pfenex?

Pfenex's mailing address is 10790 Roselle St, SAN DIEGO, CA 92121-1508, United States. The biotechnology company can be reached via phone at +1-858-3524400.

MarketBeat Community Rating for Pfenex (PFNX)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  121 (Vote Outperform)
Underperform Votes:  90 (Vote Underperform)
Total Votes:  211
MarketBeat's community ratings are surveys of what our community members think about Pfenex and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Pfenex (NYSEAMERICAN:PFNX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score:
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $8.00$8.00$8.00N/A
Price Target Upside: 151.57% upside151.57% upside151.57% upsideN/A

Pfenex (NYSEAMERICAN:PFNX) Consensus Price Target History

Price Target History for Pfenex (NYSEAMERICAN:PFNX)

Pfenex (NYSEAMERICAN:PFNX) Analyst Ratings History

DateBrokerageActionRatingPrice TargetDetails
11/10/2017JMP SecuritiesLower Price TargetPositive -> Outperform$21.00 -> $8.00View Rating Details
9/8/2017William BlairReiterated RatingOurperformView Rating Details
8/9/2016MizuhoLower Price TargetBuy$22.00 -> $18.00View Rating Details
5/24/2016BarclaysLower Price TargetOverweight$28.00 -> $14.00View Rating Details
(Data available from 2/19/2016 forward)


Pfenex (NYSEAMERICAN:PFNX) Earnings History and Estimates Chart

Earnings by Quarter for Pfenex (NYSEAMERICAN:PFNX)

Pfenex (NYSEAMERICAN PFNX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/13/2018($0.49)N/AView Earnings Details
11/9/2017Q3 2017($0.54)($0.37)$3.30 million$5.02 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.46)($0.52)$3.10 million$3.03 millionViewListenView Earnings Details
5/8/2017Q1 2017($0.57)($0.43)$2.50 million$2.80 millionViewListenView Earnings Details
3/15/2017Q4 2016($0.66)($0.45)$2.50 million$5.47 millionViewN/AView Earnings Details
11/9/2016Q316($0.56)$1.46$3.18 million$48.82 millionViewListenView Earnings Details
8/8/2016Q216($0.47)($0.43)$2.55 million$3.10 millionViewN/AView Earnings Details
5/9/2016Q116($0.45)($0.35)$2.35 million$2.76 millionViewN/AView Earnings Details
3/10/2016Q415($0.59)($0.37)$2.56 million$3.30 millionViewListenView Earnings Details
11/13/2015Q315($0.46)($0.33)$2.05 million$2.06 millionViewListenView Earnings Details
8/13/2015Q215($0.39)($0.27)$2.07 million$2.30 millionViewListenView Earnings Details
5/14/2015Q115($0.24)($0.29)$2.10 million$2.00 millionViewListenView Earnings Details
3/16/2015Q4($0.20)($0.18)$2.05 million$2.02 millionViewN/AView Earnings Details
11/13/2014Q3($0.25)($0.16)$2.13 million$2.80 millionViewN/AView Earnings Details
8/29/2014($0.15)($1.67)$1.75 million$3.27 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)


Pfenex (NYSEAMERICAN:PFNX) Earnings Estimates

No earnings estimates for this company have been tracked by


Dividend History for Pfenex (NYSEAMERICAN:PFNX)

No dividend announcements for this company have been tracked by

Insider Trades

Pfenex (NYSEAMERICAN PFNX) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for Pfenex (NYSEAMERICAN:PFNX)
Insider Trades by Quarter for Pfenex (NYSEAMERICAN:PFNX)

Pfenex (NYSEAMERICAN PFNX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/12/2017Jason Grenfell-GardnerDirectorBuy10,000$4.51$45,100.0010,000View SEC Filing  
5/16/2017Patricia LadyInsiderSell2,000$4.78$9,560.00View SEC Filing  
1/6/2017Signet Healthcare Partners AccMajor ShareholderSell400$9.50$3,800.00View SEC Filing  
1/5/2017Signet Healthcare Partners AccMajor ShareholderSell7,710$9.50$73,245.00View SEC Filing  
12/29/2016Signet Healthcare Partners AccMajor ShareholderSell24,104$9.66$232,844.64View SEC Filing  
12/27/2016Signet Healthcare Partners AccMajor ShareholderSell104,600$9.58$1,002,068.00View SEC Filing  
12/22/2016Signet Healthcare Partners AccMajor ShareholderSell10,896$9.61$104,710.56View SEC Filing  
11/21/2016Patricia LadyInsiderSell2,000$9.87$19,740.004,800View SEC Filing  
11/15/2016Patrick K. LucyInsiderSell5,000$10.04$50,200.00View SEC Filing  
8/18/2016Patricia LadyInsiderSell2,000$9.42$18,840.00View SEC Filing  
5/24/2016Patricia LadyCAOSell2,000$6.52$13,040.004,100View SEC Filing  
5/24/2016Patricia LadyCAOSell2,000$6.52$13,040.004,100View SEC Filing  
12/15/2015Chemical Co /De/ DowMajor ShareholderSell600,000$11.75$7,050,000.002,221,428View SEC Filing  
12/3/2015Patrick K LucyInsiderSell1,500$14.15$21,225.00105,690View SEC Filing  
12/1/2015Bertrand C. LiangCEOSell5,000$14.88$74,400.00522,466View SEC Filing  
12/1/2015Henry W Jr. TalbotVPSell2,000$15.08$30,160.00118,678View SEC Filing  
11/18/2015Patricia LadyCAOSell2,000$14.05$28,100.001,400View SEC Filing  
11/4/2015Patrick K. LucyinsiderSell1,500$17.54$26,310.00107,190View SEC Filing  
11/2/2015Bertrand C LiangCEOSell5,000$18.01$90,050.00527,466View SEC Filing  
10/2/2015Patrick K LucyInsiderSell1,500$14.98$22,470.00108,690View SEC Filing  
10/1/2015Bertrand C LiangCEOSell5,000$14.78$73,900.00532,466View SEC Filing  
9/3/2015Patricia LadyCAOSell2,000$20.48$40,960.001,400View SEC Filing  
9/3/2015Patrick K LucyInsiderSell1,500$20.91$31,365.00110,190View SEC Filing  
9/1/2015Bertrand C. LiangCEOSell5,000$21.02$105,100.00536,980View SEC Filing  
7/6/2015Patrick K LucyInsiderSell1,500$19.17$28,755.00View SEC Filing  
7/1/2015Bertrand C LiangCEOSell5,000$19.63$98,150.00View SEC Filing  
6/3/2015Patrick K LucyInsiderSell1,500$20.08$30,120.00View SEC Filing  
6/1/2015Bertrand C LiangCEOSell5,000$18.70$93,500.00View SEC Filing  
5/4/2015Patrick K LucyInsiderSell1,500$13.25$19,875.00View SEC Filing  
5/1/2015Bertrand C LiangCEOSell5,000$13.49$67,450.00View SEC Filing  
4/29/2015Chemical Co /De/ DowMajor ShareholderSell2,232,233$14.57$32,523,634.81View SEC Filing  
4/29/2015James C GaleDirectorSell1,907,767$14.57$27,796,165.19View SEC Filing  
4/2/2015Patrick K LucyInsiderSell1,500$17.62$26,430.00View SEC Filing  
4/1/2015Bertrand C LiangCEOSell5,000$15.27$76,350.00View SEC Filing  
3/4/2015Patrick K LucyInsiderSell1,500$14.36$21,540.00View SEC Filing  
7/29/2014Signet Healthcare Partners AccMajor ShareholderSell380,867$0.31$118,068.77View SEC Filing  
(Data available from 1/1/2013 forward)


Pfenex (NYSEAMERICAN PFNX) News Headlines

Pfenex Inc (PFNX) Short Interest UpdatePfenex Inc (PFNX) Short Interest Update - February 9 at 6:36 PM
Pfenex Inc (PFNX) Short Interest Up 33.2% in JanuaryPfenex Inc (PFNX) Short Interest Up 33.2% in January - January 24 at 5:40 PM
Short Interest in Pfenex Inc (PFNX) Increases By 13.4%Short Interest in Pfenex Inc (PFNX) Increases By 13.4% - January 10 at 6:06 PM
Pfenex (PFNX) Downgraded to "Sell" at Zacks Investment ResearchPfenex (PFNX) Downgraded to "Sell" at Zacks Investment Research - January 7 at 11:53 AM
Pfenex Names Susan A. Knudson as Chief Financial OfficerPfenex Names Susan A. Knudson as Chief Financial Officer - January 4 at 10:05 AM
Pfênex, Inc. :PFNX-US: Earnings Analysis: Q3, 2017 By the Numbers : January 1, 2018Pfênex, Inc. :PFNX-US: Earnings Analysis: Q3, 2017 By the Numbers : January 1, 2018 - January 1 at 10:01 AM
Pfenex Inc to Post FY2017 Earnings of ($1.11) Per Share, William Blair Forecasts (PFNX)Pfenex Inc to Post FY2017 Earnings of ($1.11) Per Share, William Blair Forecasts (PFNX) - December 21 at 8:40 AM
Pfenex earns $18.5 million in milestones and updates Worldwide License and Option Agreement with Jazz PharmaceuticalsPfenex earns $18.5 million in milestones and updates Worldwide License and Option Agreement with Jazz Pharmaceuticals - December 19 at 10:12 AM
Zacks Investment Research Downgrades Pfenex Inc. (PFNX) to HoldZacks Investment Research Downgrades Pfenex Inc. (PFNX) to Hold - November 19 at 11:36 PM

SEC Filings


This page is loading this company's SEC Filings. Please wait...

Social Media


Financials are not available for this stock.


Pfenex (NYSEAMERICAN PFNX) Stock Chart for Monday, February, 19, 2018

Loading chart…

This page was last updated on 2/19/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.